By writer to www.infectiousdiseaseadvisor.com
In the USA between 2005 and 2014, inpatient prevalence of hepatitis A virus (HAV) in kidney transplant recipients was 23.42 circumstances per 100,000 admissions, and hospitalization for HAV after kidney transplantation was related to elevated intensive care unit (ICU) keep, coexisting hepatitis B and C an infection, and liver failure, in line with outcomes of a examine printed within the European Journal of Gastroenterology & Hepatology.1
Hospitalization charges for HAV an infection among the many normal inhabitants
in the USA decreased between 2002 and 2011,2 nonetheless knowledge
on epidemiology of HAV an infection in kidney transplant recipients are missing. Furthermore,
earlier research have proven a poor response to HAV vaccination amongst recipients
of kidney transplantation.3,4
Due to this fact, researchers performed a examine utilizing a big US inpatient
database between 2005 and 2014 to guage the hospitalization fee for HAV
amongst kidney transplant recipients and its outcomes in addition to useful resource
utilization, when put next with kidney transplant recipients with out HAV.1
Of 871,024 kidney transplant recipients recognized, 204 had HAV;
subsequently, the general inpatient prevalence of HAV on this affected person inhabitants was
23.42 circumstances per 100,000 admissions. Researchers discovered that there have been no
statistically important modifications within the inpatient prevalence of HAV in kidney
transplant recipients throughout the examine interval (P = .77).
Amongst hospitalized kidney transplant recipients with HAV, 27.9% had been from the Northeast, 29.2% had been from the Midwest, 23.8% had been from the South, and 19.1% had been from the West. HAV was not considerably related to elevated hospital mortality, multiorgan failure, want for belly ultrasound, hospital size of keep, and whole hospitalization prices and prices when put next with these with out HAV. Nonetheless, it was considerably related to an elevated ICU keep, coexisting hepatitis B and C infection, and liver failure.
The examine authors concluded that, “Our examine is the primary to
exhibit the hospitalization fee/pattern for HAV amongst [kidney transplant] recipients
between years 2005 and 2014.”1
- Cheungpasitporn W, Thongprayoon C, Ungprasert P, et al. Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005–2014. Eur J Gastroenterol Hepatol. 2020:32(5);650-655.
- Collier MG, Tong X, Xu F. Hepatitis A hospitalizations in the United States, 2002-2011. Hepatology. 2015;61(2):481-485.
- Jeon HJ, Ro H, Jeong JC, et al. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transpl Infect Dis. 2014;16(3):511-515.
- Stark Okay, Günther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis. 1999;180(6):2014-2017.